Escitalopram was compared to placebo in moderately severely depressed patients primary care with citalopram as the active reference. Patients were randomized receive flexible doses of 10–20 mg/day escitalopram (n=155), 20–40 (n=160), or (n=154) over an 8-week double-blind period. The efficacy parameter change from baseline last assessment Montgomery–Asberg Depression Rating Scale total score. produced a statistically significant therapeutic difference 2.9 points (P=0.002) placebo, and...

The safety and tolerability of vortioxetine in adults with major depressive disorder was assessed. Tolerability based on the nature, incidence severity treatment-emergent adverse events (TEAEs) during acute (6/8) week treatment 11 randomized, double-blind placebo-controlled short-term studies disorder: six an active reference. Symptoms following discontinuation were assessed through Discontinuation-Emergent Signs checklist three studies. Long-term (⩽52 weeks) evaluated five open-label...

Escitalopram is the active S-enantiomer of citalopram. In a chronic mild stress model depression in rats, treatments with both escitalopram and citalopram were effective; however, faster time to onset efficacy compared vehicle treatment was observed for escitalopram-treated (5 mg/kg/day) than citalopram-treated (10 rats at Week 1. To study predictability this observation clinic, we analysed 4-week data from an 8-week, double-blind, randomised, placebo-controlled, flexible-dose that placebo...

Objective: A randomized, double-blind, 24‐week fixed-dose study comparing the efficacy and safety of escitalopram to that citalopram was conducted in primary care patients with moderate severe major depressive disorder (MDD).Research design methods: This a study. Patients were randomly assigned treatment 10 mg/day (n = 175) or 20 182). Clinical response evaluated using Montgomery–Åsberg Depression Rating Scale (MADRS) Global Impression-Severity (CGI‐S) scale. The prospectively defined...

Objective Evaluate the long-term safety and efficacy of vortioxetine in management major depressive disorder (MDD) two open-label one-year studies, including a post-hoc analysis its effects on symptoms related to anhedonia.Methods Both studies were 52-week, open-label, flexible-dose extension evaluate adult patients with MDD following prior double-blind studies. Patients first study (NCT00761306) flexibly treated 5 or 10 mg/day (N = 74), second (NCT01323478) received 15 20 71).Results The...

Administration of the same Quality Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) in major depressive disorder (MDD) generalized anxiety (GAD) before after treatment allowed us to compare quality life enjoyment satisfaction these two disorders outcome based on symptoms versus functioning. Q-LES-Q symptom-specific Montgomery–Åsberg Depression Rating Scale (MADRS) Hamilton Anxiety (HAMA) data from eight randomized, 8-week, double-blind, placebo-controlled clinical trials with...

The multimodal antidepressant vortioxetine is effective in reducing somatic symptoms patients with major depressive disorder (MDD), but little known about its effects common comorbid physical illnesses.This was a pooled analysis of 13 randomized, placebo-controlled trials which evaluated the efficacy (using Montgomery-Åsberg Depression Rating Scale [MADRS]) and safety (5-20 mg/day) adult MDD. We stable conditions that were verified by diagnosis had sufficient database representation.Of 5982...

Major depressive disorder (MDD) affects >163 million people worldwide and is a leading cause of disability in China. Functional impairment occurs alongside cognitive symptoms, anxiety, depression, reducing quality life productivity patients with MDD.The multimodal antidepressant vortioxetine has demonstrated efficacy relieving functional symptoms MDD randomized controlled trials (RCTs). The RELIEVE China study aimed to investigate the real-world effectiveness China.This was an observational,...

Escitalopram has been proven safe and efficacious in the treatment of major depressive disorder (MDD) short-term studies. The long-term clinical tolerability response to are presented from a 12-month open-label study with total exposure time escitalopram 486 patient years.Patients (n = 590) MDD entered after completing one two 8-week, double-blind, placebo-controlled, lead-in studies primary care. was administered at doses 10 or 20 mg/day (dose based on physician's judgement) an average 315...

It is previously reported that the Montgomery–Åsberg Depression Rating Scale (MADRS) anhedonia factor score correlated with scales assessing function in patients major depressive disorder (MDD). This was an analysis of a database including 5 long-term, extension studies prior controlled trials, which evaluated effects open-label, maintenance treatment vortioxetine (5-20 mg/day over 1-year) adults MDD. We assessed association changes MADRS scores Clinical Global Impression Severity (CGI-S),...

Abstract: Escitalopram is the active S‐enantiomer of citalopram. In a chronic mild stress model depression in rats, treatments with both escitalopram and citalopram were effective; however, faster time to onset efficacy compared vehicle treatment was observed for escitalopram‐treated (5 mg/kg/day) than citalopram‐treated (10 rats at Week 1. To study predictability this observation clinic, we analysed 4‐week data from an 8‐week, double‐blind, randomised, placebo‐controlled, flexible‐dose that...

To test whether satisfaction with taking medication, assessed using item 15 of the Quality Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), is associated clinical outcome persistence treatment.In this post hoc analysis, data were analyzed from 4 randomized placebo-controlled studies patients major depressive disorder treated escitalopram (650 534 placebo), together 2 trials versus venlafaxine or duloxetine (235 233 a serotonin-norepinephrine reuptake inhibitor). The published between...

Background A post-marketing surveillance study was conducted to assess the real-world safety and effectiveness of vortioxetine for treatment major depressive disorder (MDD) in South Korea. Methods Adult patients aged 19–94 years receiving MDD at 72 hospitals clinics Korea between 19 th August 2014 18 2020 were included. Patients followed up 24±2 weeks, three visits. Adverse events (AEs) effectiveness, assessed by both clinician patient-reported measures, analyzed. Results total 3,263 (mean...

Objectives This study aimed to evaluate the risk of suicidal ideation and behavior associated with vortioxetine treatment in adults major depressive disorder (MDD). Methods Suicide-related events were evaluated post hoc using 2 pools: one short-term pool 10 randomized, placebo-controlled studies (6–8 weeks) another long-term that included 3 open-label extension (52 weeks). Evaluation suicide-related was performed Columbia-Suicide Severity Rating Scale (C-SSRS) scores treatment-emergent...

Objectives: In Japan, there are currently no approved antidepressant treatments for pediatric patients with depression. This study aimed to estimate the prevalence of depression among adolescents under medical care in pharmacological used, and perceived unmet needs specialties treating population. Methods: The was conducted November 2014 as an internet survey physicians clinical practice. It included a sample 731 potential treat adolescent 161 who had treated at least one pharmacotherapy...

Two post-authorisation studies assessed the safety and persistence of patients' use nalmefene.The START study (EUPAS5678) was a non-interventional, multi-country, prospective, 18-month (8 follow-up visits) cohort including outpatients initiating nalmefene for first time. The multi-database retrospective (MDRC, EUPAS14083) included baseline data from German, Swedish UK healthcare databases. Both permitted 'all comers' without explicit exclusion criteria; predefined subgroups interest elderly...

Patients with major depressive disorder (MDD) experience symptoms such as anhedonia well cognitive dysfunction which can subsequently impair their work performance.